Despite all clinical advances in personalized therapies and their proven impact on patient’s clinical outcome, there is only one effective drug (sotorasib) [53] approved by the Food and Drug Administration (FDA) for KRAS G12C NSCLC patients [54,55]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.